Other headlinesGMI builds clinical war ches
Toshiba boosts Infinix image quality
Toshiba America Medical Systems unveiled Sept 21 a low-contrast capability for Infinix-i systems that feature mid- and large-size flat panel detectors. The new capability was a feature of its exhibit at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The Low-Contrast Imaging (LCI) technology enables better visualization of soft tissue in the angio suite, according to the company, delivering CT-like images of the liver, brain, and cerebral ventricles. LCI may be used to improve diagnosis, as well as to confirm appropriate endpoints during interventional procedures, such as aortic stent-grafting, the company said. The Infinix-i line features a five-axis C-arm that covers patients head-to-toe and fingertip-to-fingertip.
GMI builds clinical war chest
Gamma Medica-Ideas has raised $24 million to support efforts to grow its presence in the clinical marketplace with digital SPECT, PET, and CT products. Psilos Group, a healthcare venture capital firm, and Capital Resource Partners, a provider of hybrid growth financing, contributed $14 million in equity capital. Capital Resource Partners also provided $5 million in mezzanine debt. The technology lending group at Bridge Bank rounded out the financing with a $5 million revolving line of credit. Historically, GMI has served the pre-clinical imaging market, where the need for increased productivity is driving demand for medical research and drug discovery applications. Its small animal imaging products are distributed in Japan by SII NanoTechnology and elsewhere by GE Healthcare. With this financing, GMI plans to leverage its digital imaging technology platform into clinical imaging markets, where the company will promote its products as the means to improved diagnosis at lower costs. GMI’s initial product, LumaGEM, is focused on improving the diagnosis of cancers in women with dense breast tissue.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.